2,3-Dihydroxy-Benzoic Acid

Identification

Generic Name
2,3-Dihydroxy-Benzoic Acid
DrugBank Accession Number
DB01672
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 154.1201
Monoisotopic: 154.02660868
Chemical Formula
C7H6O4
Synonyms
Not Available
External IDs
  • NSC-27435

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
U2,3-dihydroxybenzoate-AMP ligaseNot AvailableBacillus subtilis (strain 168)
UNeutrophil gelatinase-associated lipocalinNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as salicylic acids. These are ortho-hydroxylated benzoic acids.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Salicylic acids
Alternative Parents
Benzoic acids / Catechols / Benzoyl derivatives / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organooxygen compounds / Organic oxides
show 1 more
Substituents
1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / Aromatic homomonocyclic compound / Benzoic acid / Benzoyl / Carboxylic acid / Carboxylic acid derivative / Catechol / Hydrocarbon derivative / Monocarboxylic acid or derivatives
show 6 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
dihydroxybenzoic acid (CHEBI:18026)
Affected organisms
Not Available

Chemical Identifiers

UNII
70D5FBB392
CAS number
303-38-8
InChI Key
GLDQAMYCGOIJDV-UHFFFAOYSA-N
InChI
InChI=1S/C7H6O4/c8-5-3-1-2-4(6(5)9)7(10)11/h1-3,8-9H,(H,10,11)
IUPAC Name
2,3-dihydroxybenzoic acid
SMILES
OC(=O)C1=CC=CC(O)=C1O

References

General References
Not Available
Human Metabolome Database
HMDB0000397
KEGG Compound
C00196
PubChem Compound
19
PubChem Substance
46504857
ChemSpider
18
BindingDB
92456
ChEBI
18026
ChEMBL
CHEMBL1432
ZINC
ZINC000000388166
PDBe Ligand
DBH
PDB Entries
1l6m / 1md9 / 1mdb / 2why / 3by0 / 3cmp / 3k3l / 3sao / 3t1d / 3tf6
show 3 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)204 °CPhysProp
logP1.20HANSCH,C ET AL. (1995)
pKa2.91 (at 25 °C)SERJEANT,EP & DEMPSEY,B (1979)
Predicted Properties
PropertyValueSource
Water Solubility6.88 mg/mLALOGPS
logP1.42ALOGPS
logP1.67Chemaxon
logS-1.4ALOGPS
pKa (Strongest Acidic)2.56Chemaxon
pKa (Strongest Basic)-6.3Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area77.76 Å2Chemaxon
Rotatable Bond Count1Chemaxon
Refractivity37.28 m3·mol-1Chemaxon
Polarizability13.7 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.8051
Blood Brain Barrier-0.6225
Caco-2 permeable-0.5611
P-glycoprotein substrateNon-substrate0.6639
P-glycoprotein inhibitor INon-inhibitor0.9825
P-glycoprotein inhibitor IINon-inhibitor0.994
Renal organic cation transporterNon-inhibitor0.9415
CYP450 2C9 substrateNon-substrate0.8198
CYP450 2D6 substrateNon-substrate0.9193
CYP450 3A4 substrateNon-substrate0.7265
CYP450 1A2 substrateNon-inhibitor0.9274
CYP450 2C9 inhibitorNon-inhibitor0.9363
CYP450 2D6 inhibitorNon-inhibitor0.9693
CYP450 2C19 inhibitorNon-inhibitor0.9782
CYP450 3A4 inhibitorNon-inhibitor0.8427
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9318
Ames testNon AMES toxic0.9146
CarcinogenicityNon-carcinogens0.9177
BiodegradationReady biodegradable0.8936
Rat acute toxicity1.8670 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9821
hERG inhibition (predictor II)Non-inhibitor0.9599
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-0a4i-0924000000-1ed6156dbe82344d29af
GC-MS Spectrum - GC-MS (3 TMS)GC-MSsplash10-0a4u-3922000000-0b326da278c57df03c1a
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0zg0-4900000000-44419ba3a3e768caaeee
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0a4i-0924000000-1ed6156dbe82344d29af
GC-MS Spectrum - GC-MSGC-MSsplash10-0a4u-3922000000-0b326da278c57df03c1a
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0a4l-0922000000-beddd6836f31d4813a14
MS/MS Spectrum - Quattro_QQQ 10V, NegativeLC-MS/MSsplash10-0zfr-0900000000-9d9306f70123d5d263ef
MS/MS Spectrum - Quattro_QQQ 25V, NegativeLC-MS/MSsplash10-0a4i-4900000000-702a14e999a2e830a9d5
MS/MS Spectrum - Quattro_QQQ 40V, NegativeLC-MS/MSsplash10-0a4i-7900000000-a88a9646fb3070aef98d
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0a4i-0900000000-9bbc26971da28557772e
MS/MS Spectrum - , negativeLC-MS/MSsplash10-0pb9-0900000000-7f5ec409ec11ea326d42
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0a4i-0900000000-ba9640b66d655cdb3295
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0201-0900000000-40f4ec4c2b33e147f78b
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-052r-0900000000-7c81dbd866a1fb552d52
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0900000000-357714578f42ce437db8
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0pc0-8900000000-cb0b3980891b50a0bbec
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-9700000000-f99905dc9b99b1b7b07d
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0zi0-9000000000-b4bb3281077ef1323579
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-9000000000-e82d726f6a2dbf0f43eb
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-130.5294784
predicted
DarkChem Lite v0.1.0
[M-H]-130.4714784
predicted
DarkChem Lite v0.1.0
[M-H]-130.4134784
predicted
DarkChem Lite v0.1.0
[M-H]-130.4793784
predicted
DarkChem Lite v0.1.0
[M-H]-127.90746
predicted
DeepCCS 1.0 (2019)
[M+H]+131.3276784
predicted
DarkChem Lite v0.1.0
[M+H]+132.0714784
predicted
DarkChem Lite v0.1.0
[M+H]+136.4503784
predicted
DarkChem Lite v0.1.0
[M+H]+131.9608784
predicted
DarkChem Lite v0.1.0
[M+H]+130.68471
predicted
DeepCCS 1.0 (2019)
[M+Na]+131.1914784
predicted
DarkChem Lite v0.1.0
[M+Na]+131.1663784
predicted
DarkChem Lite v0.1.0
[M+Na]+131.0851784
predicted
DarkChem Lite v0.1.0
[M+Na]+131.2120784
predicted
DarkChem Lite v0.1.0
[M+Na]+139.71727
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Bacillus subtilis (strain 168)
Pharmacological action
Unknown
General Function
Ligase activity
Specific Function
Activation of the carboxylate group of 2,3-dihydroxy-benzoate (DHB), via ATP-dependent PPi exchange reactions, to the acyladenylate.
Gene Name
dhbE
Uniprot ID
P40871
Uniprot Name
2,3-dihydroxybenzoate-AMP ligase
Molecular Weight
59927.77 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Transporter activity
Specific Function
Iron-trafficking protein involved in multiple processes such as apoptosis, innate immunity and renal development. Binds iron through association with 2,5-dihydroxybenzoic acid (2,5-DHBA), a siderop...
Gene Name
LCN2
Uniprot ID
P80188
Uniprot Name
Neutrophil gelatinase-associated lipocalin
Molecular Weight
22587.915 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:51